Pharmacokinetics of pantoprazole in man

被引:0
|
作者
Huber, R
Hartmann, M
Bliesath, H
Luhmann, R
Steinijans, VW
Zech, K
机构
关键词
proton pump inhibitor; pharmacokinetics; drug interaction; pantoprazole;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the treatment of acid-related gastrointestinal diseases such as reflux esophagitis, duodenal and gastric ulcers. Pantoprazole, administered as a 40 mg enteric coated tablet, is quantitatively absorbed. Its absolute bioavailability is 77% and does not change upon multiple dosing. Following a single oral dose of 40 mg, C-max is approximately 2.5 mg/l, with a t(max) of 2-3 h. The AUC((O,inf.)) is approximately 5 mgxh/l. Pantoprazole shows linear pharmacokinetics after both i.v. and oral administration. Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins. Elimination half-life, clearance and volume of distribution are independent of the dose. The main serum metabolite is formed by demethylation at the 4-position of the pyridine ring, followed by conjugation with sulphate, Almost 80% of an oral or intravenous dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion. The pharmacokinetics of pantoprazole are unaltered in patients with renal failure. In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h, The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly. Concomitant intake of food had no influence on the bioavailability of pantoprazole. Pantoprazole showed lack of cytochrome P450 interaction with concomitantly administered drugs in any of the studies conducted to date. Lack of interaction was also demonstrated with a coadministered antacid, The absence of inductive effects on metabolism after chronic administration was first shown by using antipyrine as a probe for mixed functional oxidative cytochrome P450 enzymes, Absence of CYP1A2 induction was confirmed using the specific probe caffeine, As sensitive probes for CYP3A enzyme induction, urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol were also unchanged.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetics of pantoprazole in man
    Huber, R
    Hartmann, M
    Bliesath, H
    Luhmann, R
    Steinijans, VW
    Zech, K
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 : S7 - S16
  • [3] Pharmacokinetics and metabolism of the proton pump inhibitory pantoprazole in man
    Radhofer-Welte, S
    DRUGS OF TODAY, 1999, 35 (10): : 765 - 772
  • [4] Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man.
    Koch, HJ
    Hartmann, M
    Bliesath, H
    Huber, R
    Steinijans, VW
    Mascher, H
    Wurst, W
    GASTROENTEROLOGY, 1996, 110 (04) : A158 - A158
  • [5] Pharmacokinetics and relative bioavailability of pantoprazole
    Zhao, Limei
    Jian, Lingyan
    Duan, Xu
    Zhongguo Yaoxue Zazhi/Chinese Pharmaceutical Journal, 2000, 35 (05): : 329 - 331
  • [6] NO INFLUENCE OF PANTOPRAZOLE ON THE PHARMACOKINETICS OF PHENYTOIN
    MIDDLE, MV
    MULLER, FO
    SCHALL, R
    GROENEWOUD, G
    HUNDT, HKL
    HUBER, R
    BLIESATH, H
    STEINIJANS, VW
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1995, 33 (05) : 304 - 307
  • [7] No influence of pantoprazole on the pharmacokinetics of phenytoin
    Middle, MV
    Muller, FO
    Schall, R
    Groenewoud, G
    Hundt, HKL
    Huber, R
    Bliesath, H
    Steinijans, VW
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 : S72 - S75
  • [8] Efficacy and Pharmacokinetics of Pantoprazole in Alpacas
    Smith, G. W.
    Davis, J. L.
    Smith, S. M.
    Gerard, M. P.
    Campbell, N. B.
    Foster, D. M.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (04): : 949 - 955
  • [9] Pharmacokinetics of intravenous pantoprazole in children
    L'Italien, C
    Theoret, Y
    Drouin, C
    Hardy, P
    Nguyen, B
    Dirks, M
    Delvin, E
    Faure, C
    GASTROENTEROLOGY, 2003, 124 (04) : A231 - A231
  • [10] THE H+,K+-ATPASE INHIBITOR PANTOPRAZOLE DOES NOT INFLUENCE THE PHARMACOKINETICS OF PHENYTOIN IN MAN
    MULLER, FO
    BLIESATH, H
    MIDDLE, MV
    HUNDT, HKL
    HARTMANN, M
    SCHALL, R
    STEINIJANS, VW
    HUBER, R
    WURST, W
    GASTROENTEROLOGY, 1994, 106 (04) : A144 - A144